Skip to main content
. Author manuscript; available in PMC: 2016 Mar 2.
Published in final edited form as: Cancer Cell Microenviron. 2016;3(1):e1116. doi: 10.14800/ccm.1116

Table 3.

Univariate Analysis of the Effects of Different Variables on 3- and 5-Year Overall Survival (OS) Rates

Variable HR (95% CI) 3-Year OS rate (95% CI) 5-Year OS rate (95% CI) p Value
All patients 0.87 (0.84-0.89) 0.78 (0.75-0.82)
Age, years (continuous) 1.05 (1.03-1.06) < 0.0001
Age, years < 0.0001
< 65 0.93 (0.9-0.96) 0.88 (0.84-0.92)
≥ 65 0.82 (0.78-0.86) 0.71 (0.67-0.76)
BMI (continuous) 0.97 (0.95-1.00) 0.157
BMI 0.254
≤ 25 0.86 (0.82-0.9) 0.76 (0.71-0.82)
> 25 0.87 (0.84-0.9) 0.8 (0.76-0.84)
Gender < 0.0001
Male 0.81 (0.77-0.85) 0.7 (0.65-0.75)
Female 0.92 (0.89-0.94) 0.86 (0.82-0.9)
ASA physical status 0.011
1-2 0.98 (0.95-1) 0.93 (0.86-0.99)
3-4 0.85 (0.83-0.88) 0.77 (0.73-0.8)
Adenocarcinoma 0.088
No 0.83 (0.78-0.87) 0.75 (0.7-0.81)
Yes 0.89 (0.87-0.92) 0.81 (0.77-0.85)
Type of surgery 0.180
Thoracotomy 0.86 (0.83-0.89) 0.77 (0.73-0.81)
Thoracoscopy 0.89 (0.85-0.93) 0.83 (0.78-0.88)
Neoadjuvant chemotherapy 0.112
No 0.87 (0.85-0.9) 0.79 (0.76-0.83)
Yes 0.78 (0.69-0.9) 0.69 (0.58-0.83)
Neoadjuvant radiation 0.824
No 0.87 (0.84-0.89) 0.78 (0.75-0.82)
Yes 0.75 (0.43-1) 0.75 (0.43-1)
Adjuvant chemotherapy 0.486
No 0.87 (0.84-0.89) 0.78 (0.75-0.82)
Yes 0.87 (0.81-0.95) 0.81 (0.73-0.9)
Adjuvant radiation 0.147
No 0.87 (0.84-0.89) 0.79 (0.76-0.82)
Yes 0.77 (0.62-0.97) 0.58 (0.38-0.86)
NLR (continuous) 1.16 (1.1-1.22) < 0.0001
NLR < 0.0001
< 5 0.88 (0.85-0.9) 0.8 (0.77-0.83)
≥ 5 0.7 (0.58-0.84) 0.56 (0.43-0.72)
Hb (continuous) 0.87 (0.79-0.96) 0.005
Preoperative anemia 0.0001
Yes 0.78 (0.72-0.85) 0.64 (0.57-0.73)
No 0.89 (0.86-0.92) 0.82 (0.79-0.86)
Blood transfusion 0.0001
No 0.88 (0.85-0.9) 0.8 (0.77-0.83)
Yes 0.73 (0.63-0.84) 0.61 (0.49-0.75)

HR = hazard ratio; CI = confidence interval; BMI = body mass index; ASA = American Society of Anesthesiologists; NLR = neutrophil-to-lymphocyte ratio; Hb: hemoglobin.